Journal of Clinical Immunology

, Volume 24, Issue 1, pp 30–36 | Cite as

Increased CD8+ T Cell Apoptosis in Scleroderma Is Associated with Low Levels of NF-κB

  • Aharon Kessel
  • Itzhak Rosner
  • Michael Rozenbaum
  • Devy Zisman
  • Anca Sagiv
  • Zehava Shmuel
  • Edmond Sabo
  • Elias Toubi
Article

Abstract

Our Objectives were (1) to compare lymphocyte subpopulation apoptosis rates in SSc patients versus healthy controls and (2) to compare Bcl-2 and NF-κB expression in cultured CD8 lymphocytes of SSc patients versus controls. Peripheral blood samples were obtained from 27 SSc patients meeting the American College of Rheumatology criteria for SSc and 28 healthy individuals. Mononuclear cells were isolated by Ficoll–Hypaque density gradient separation and cultured for 48 hr. For determination of apoptosis within specific cell populations, samples were labeled with PE-conjugated monoclonal antibody to CD8, CD4, and a FITC-conjugated monoclonal antibody to Annexin V. Flow cytometry was carried out with a FACS operating with Cellquest software. CD8+ lymphocytes were positively selected with magnetic microbeads conjugated to antihuman CD8. CD8 T cells were separated, then incubated with activation for 48 hr, and NF-κB and Bcl-2 analysis was carried out using Western immunoblotting. The CD4:CD8 ratio was increased in SSc compared to controls (2.6 ± 1.13 vs.1.87 ± 0.76; P = 0.018). The spontaneous apoptosis rate of SSc CD8 lymphocytes was increased compared to that of controls of (21.9 ± 13.7 vs. 13.3 ± 9.9; P = 0.019). No difference was found in the rate of CD4 apoptosis of SSc patients versus controls (9.8 ± 5.2 vs. 7.18 ± 4.89%; P = ns). The expression of NF-κB in SSc CD8 lymphocytes was decreased compared with that of CD8 lymphocytes from healthy controls (144 ± 13 vs. 188 ± 11; P = 0.018). Whereas expression of Bcl-2 was similar in activated CD8+ T cells of SSc patients and healthy controls, CD8+ T cell apoptosis rate was found to be in reverse correlation with expression of NFkB in these cells (r = −0.53, P = 0.029). The increased CD4:CD8 ratio in SSC may result from increased CD8+ T cell apoptosis. Increased SSc CD8 T cell apoptosis is associated with low levels of NF-κB.

Scleroderma apotosis CD4:CD8 ratio NF-κB 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    LeRoy EC, Trojanowska M, Smith EA: The pathogenesis of scleroderma(systemic sclerosis, SSc). Clin Exp Rheumatol 9: 173-177, 1991Google Scholar
  2. 2.
    White B: Immunopathogenesis of systemic sclerosis. Rheum Dis Clin North Am 22: 695-708, 1996Google Scholar
  3. 3.
    Postlethwaite AE: A role of T cell and cytokines in effecting fibrosis. Int Rev Immunol 12: 247-258, 1995Google Scholar
  4. 4.
    Roumm AD, Whiteside TL, Medsger TA Jr, Rodnan GP: Lymphocytes in the skin of patients with progressive systemic sclerosis: quantification, sub-typing and clinical correlations. Arth Rheum 27: 645-653, 1984Google Scholar
  5. 5.
    Yurovsky VV, Wigley FM, Wise RA, White B: Skewing of the CD8+ T cell repertoire in the lungs of patients with systemic sclerosis. Hum Immunol 48: 84-97, 1996Google Scholar
  6. 6.
    Fiocco U, Rosada M, Cozzi L, et al.: Early phenotypic activation of circulating helper memory T cells in scleroderma: Correlation with disease severity. Ann Rheum Dis 52: 272-277, 1993Google Scholar
  7. 7.
    Gustafsson R, Totterman TH, Klareskog L, Hallgren R: Increase in activated T cells and reduction in suppressor inducer T cells in systemic sclerosis. Ann Rheum Dis 49: 40-45, 1990Google Scholar
  8. 8.
    Clements PJ, Peter JB, Agopian MS, Telian NS, Furst DE: Elevated serum levels of soluble interleukin 2 receptor, interleukin 2 and neopterin in diffuse and limited scleroderma: effect of chlorambucil. J Rheumatol 17: 908-910, 1990Google Scholar
  9. 9.
    Kantor TV, Friberg D, Medsger TA Jr, Buckingham RB, Whiteside TL: Cytokine production and serum levels in systemic sclerosis. Clin Immunol Immunopathol 65: 278-285, 1992Google Scholar
  10. 10.
    Whiteside TL, Kumagai Y, Roumm AD, Almendinger R, Rodnan GP: Suppressor cell function and T lymphocyte subpopulations in peripheral blood of patients with progressive systemic sclerosis. Arth Rheum 26: 841-847, 1983Google Scholar
  11. 11.
    Barnett AJ, Tait BD, Barnett MA, Toh BH: T lymphocyte subset abnormalities and HLA antigens in scleroderma (systemic sclerosis). Clin Exp Immunol 76: 24-29, 1989Google Scholar
  12. 12.
    Degiannis D, Seibold JR, Czarnecki M, Raskova J, Raska K Jr: Soluble and cellular markers of immune activation in patients with systemic sclerosis. Clin Immunol Immunopathol 56: 259-270, 1990Google Scholar
  13. 13.
    Dau PC, Callahan JP: Immune modulation during treatment of systemic sclerosis with plasmapheresis and immunosuppressive drugs. Clin Immunol Immunopathol 70: 159-165, 1994Google Scholar
  14. 14.
    Freundlich B, Jimenez SA: Phenotype of peripheral blood lymphocytes in patients with progressive systemic sclerosis: Activated T lymphocytes and the effect of D-penicillamine therapy. Clin Exp Immunol 69: 375-384, 1987Google Scholar
  15. 15.
    Keystone EC, Lau C, Galdman DD, Wilkinson S, Lee P, Shore A: Immunoregulatory T cell subpopulations in patients with scleroderma using monoclonal antibodies. Clin Exp Immunol 48: 443-448, 1982Google Scholar
  16. 16.
    Stummvoll GH, Aringer M, Smolen JS, et al.: Derangement of apoptosis-related lymphocyte homeostasis in systemic sclerosis. Rheumatology 39: 1341-1350, 2000Google Scholar
  17. 17.
    Subcommittee for Scleroderma Criteria of American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arth Rheum 23: 581-590, 1980Google Scholar
  18. 18.
    LeRoy EC, Black C, Fleischmajer R, et al.: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15: 202-205, 1988Google Scholar
  19. 19.
    Lanza L, Scudeletti M, Puppo F, et al.: Prednisone increase apoptosis in in vitro activated human peripheral blood T lymphocyte. Clin Exp Immunol 103: 482-490, 1996Google Scholar
  20. 20.
    Towbin H, Stachelin T, Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 76: 4350-4354, 1979Google Scholar
  21. 21.
    Lowry OH, Rosebrough NJ, Farr AL, Randall R: Protein measurement with the folin reagent. J Biol Chem 193: 265-275, 1951Google Scholar
  22. 22.
    Toubi E, Adir-Shani A, Kessel A, Shmuel Z, Sabo E, Hacham H: Immune aberrations in B and T lymphocytes derived from chronic urticaria patients. J Clin Immunol 20: 371-378, 2000Google Scholar
  23. 23.
    Krammer PH, Behrmann I, Daniel P, Dhein J, Debatin KM: Regulation of apoptosis in the immune system. Curr Opin Immunol 6: 279-289, 1994Google Scholar
  24. 24.
    Vaishnaw AK, Mcnally JD, Elkon KB: Apoptosis in the rheumatic diseases. Arth Rheum 40: 1917-1927, 1997Google Scholar
  25. 25.
    Beg AA, Baltimore D: An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 274: 782-784, 1996Google Scholar
  26. 26.
    Wang CY, Mayo MW, Baldwin AS Jr: TNF and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 274: 784-787, 1996Google Scholar
  27. 27.
    Wu MX., Ao Z, Prasad KV, Wu R, Schlossman SF: IEX-IL, an apoptosis inhibitor involved in NF-[kappa]B-mediated cell survival. Science 281: 998-1001, 1998Google Scholar
  28. 28.
    Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr: NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1and c-IAP2 to suppress caspase-8 activation. Science 281: 1680-1683, 1998Google Scholar
  29. 29.
    Tzeng E, Billiar TR, Williams DL, et al.: Adenovirus-mediated inducible nitric oxide synthase gene transfer inhibits hepatocyte apoptosis. Surgery 124: 278-283, 1998Google Scholar
  30. 30.
    Toubi E, Kessel A, Goldstein L, Slobodin G, Sabo E, Shmuel Z, Zuckerman E: Enhanced peripheral T-cell apoptosis in chronic hepatitis C virus infection: association with liver disease severity. J Hepatol 35: 774-780, 2001Google Scholar
  31. 31.
    Tamatani M, Che Y, Matsuzaki H, et al.: Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NFkappaB activation in primary hippocampal neurons. J Biol Chem 274: 8531-8538, 1999Google Scholar
  32. 32.
    Zong WX, Edelstein LC, Chen C, Bash J, Gélinas C: The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kB that blocks TNFα-induced apoptosis. Genes Dev 13: 382-387, 1999Google Scholar
  33. 33.
    Wang CY, Guttridge DC, Mayo MW, Baldwin AS: NF-kB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 19: 5923-5929, 1999Google Scholar
  34. 34.
    Wong KH, Kammer GA, Dennis G, Tsokos GC: Abnormal NF-kB activity in T lymphocytes from patients with systemic lupus erythematosus is associated with decreased p65-RelA protein expression. J Immunol 163: 1682-1689, 1999Google Scholar

Copyright information

© Plenum Publishing Corporation 2004

Authors and Affiliations

  • Aharon Kessel
    • 1
  • Itzhak Rosner
    • 2
  • Michael Rozenbaum
    • 2
  • Devy Zisman
    • 3
  • Anca Sagiv
    • 1
  • Zehava Shmuel
    • 1
  • Edmond Sabo
    • 1
  • Elias Toubi
    • 1
  1. 1.Division of Clinical ImmunologyBnai-Zion Medical CenterHaifaIsrael
  2. 2.Rheumatology UnitBnai-Zion Medical CenterHaifaIsrael
  3. 3.Internal Medicine Department ACarmel Hospital, Faculty of MedicineTechnion, HaifaIsrael

Personalised recommendations